Classification Changes Impacting the Treatment of LR-MDS
A medical oncology specialist discusses how recent data and improvements in genomic profiling are changing the classification of lower-risk MDS.
EP: 1.Overview of Lower-Risk Myelodysplastic Syndromes (LR-MDS)
EP: 2.Standard-of-Care Treatment for Patients with LR-MDS
EP: 3.Erythroid Maturating Agents (EMAs) for Frontline or Second-Line Treatment of Anemia in LR-MDS
EP: 4.COMMANDS Trial: Study Design, Patient Population, and Results
Now Viewing
EP: 5.Classification Changes Impacting the Treatment of LR-MDS
EP: 6.Dose Escalation of Luspatercept on Trial and Real-World Data
EP: 7.Adverse Events with EMAs: Luspatercept
EP: 8.Current Approach for Treating Anemia in LR-MDS
EP: 9.Future Treatment for Anemia of LR-MDS
EP: 10.Clinical Pearls for Community Oncologist Treating LR-MDS
Video content above is prompted by the following:
- Two recent data presentations have reported on the impact of baseline mutational burden on clinical outcomes for ESAs and luspatercept.
- Please discuss the efficacy of ESAs in patients with very low vs. moderate low to very high IPSS-M risk groups.
- Please discuss the clinical outcomes of luspatercept vs. epoetin alfa from the COMMANDS trial based on IPSS-M risk groups (low, moderate low, moderate high and high) and baseline mutational burden.
Recent Videos
Related Content
Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS
September 5th 2024Article
During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.
Read More
Luspatercept in MDS Promotes Transfusion Independence and Anemia Response
August 21st 2024Article
During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More
